이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Iovance Biotherapeutics 미래 성장

Future 기준 확인 5/6

Iovance Biotherapeutics은 연간 수입과 매출이 각각 64.9%와 46.2% 증가할 것으로 예상되고 EPS는 연간 67.8%만큼 증가할 것으로 예상됩니다.

주요 정보

64.5%

수익 성장률

67.5%

EPS 성장률

Biotechs 수익 성장	24.4%
매출 성장률	46.5%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	20 Jun 2024

최근 미래 성장 업데이트

Recent updates

Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi

May 10

Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results

Apr 09

Iovance Biotherapeutics: Initial Amtagvi Launch In Focus

Mar 25

Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma

Feb 20

Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date

Jan 19

Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates

Sep 27

Iovance submits rolling license application to FDA for skin cancer treatment lifileucel

Aug 25

Iovance Biotherapeutics: An Unproven Biopharmaceutical Company With Significant Upside

Mar 25

Iovance Biotherapeutics: Uncertainty And Opportunity

Dec 05

Iovanve Biotherapeutics (IOVA) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow

Jun 16

Iovance Bio reports 33-month follow up data for lifileucel in advanced melanoma at ASCO21

Jun 07

Iovance: Down And Rebound

May 30

수익 및 매출 성장 예측

NasdaqGM:IOVA - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	694	-38	69	169	7
12/31/2025	391	-231	-151	-82	12
12/31/2024	150	-355	-272	-221	13
3/31/2024	2	-450	-405	-384	N/A
12/31/2023	1	-444	-384	-362	N/A
9/30/2023	1	-433	-377	-356	N/A
6/30/2023	0	-419	-355	-335	N/A
3/31/2023	N/A	-412	-333	-319	N/A
12/31/2022	N/A	-396	-313	-293	N/A
9/30/2022	N/A	-390	-294	-269	N/A
6/30/2022	N/A	-376	-296	-263	N/A
3/31/2022	N/A	-358	-278	-239	N/A
12/31/2021	N/A	-342	-266	-228	N/A
9/30/2021	N/A	-311	-290	-237	N/A
6/30/2021	N/A	-284	-281	-220	N/A
3/31/2021	N/A	-265	-259	-202	N/A
12/31/2020	N/A	-260	-252	-205	N/A
9/30/2020	N/A	-255	-223	-196	N/A
6/30/2020	N/A	-246	-208	-198	N/A
3/31/2020	N/A	-230	-202	-195	N/A
12/31/2019	N/A	-198	-166	-159	N/A
9/30/2019	N/A	-167	-140	-137	N/A
6/30/2019	N/A	-151	-125	-122	N/A
3/31/2019	N/A	-134	-114	-112	N/A
12/31/2018	N/A	-124	-102	-101	N/A
9/30/2018	N/A	-117	-92	-91	N/A
6/30/2018	N/A	-105	-85	-84	N/A
3/31/2018	N/A	-98	-78	-78	N/A
12/31/2017	N/A	-92	N/A	-79	N/A
9/30/2017	N/A	-82	N/A	-70	N/A
6/30/2017	N/A	-128	N/A	-61	N/A
3/31/2017	N/A	-116	N/A	-47	N/A
12/31/2016	N/A	-102	N/A	-33	N/A
9/30/2016	N/A	-95	N/A	-27	N/A
6/30/2016	N/A	-34	N/A	-19	N/A
3/31/2016	N/A	-29	N/A	-19	N/A
12/31/2015	N/A	-28	N/A	-18	N/A
9/30/2015	N/A	-24	N/A	-15	N/A
6/30/2015	N/A	-19	N/A	-13	N/A
3/31/2015	N/A	-15	N/A	-10	N/A
12/31/2014	N/A	-12	N/A	-9	N/A
9/30/2014	N/A	-27	N/A	-8	N/A
6/30/2014	N/A	-34	N/A	-6	N/A
3/31/2014	N/A	-35	N/A	-6	N/A
12/31/2013	N/A	-34	N/A	-4	N/A
9/30/2013	N/A	-10	N/A	-1	N/A

애널리스트 미래 성장 예측

수입 대 저축률: IOVA 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.4% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: IOVA (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: IOVA 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: IOVA 의 수익(연간 46.2% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: IOVA 의 수익(연간 46.2% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: IOVA 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Iovance Biotherapeutics 미래 성장

Future 기준 확인 5/6

주요 정보

최근 미래 성장 업데이트

Forecast to breakeven in 2026

Consensus revenue estimates increase by 11%

Price target increased by 19% to US$24.42

Consensus revenue estimates decrease by 25%

Price target decreased by 8.7% to US$20.42

Consensus revenue estimates decrease by 71%

Recent updates

Iovance Biotherapeutics, Inc. Elects Frederick G. Vogt as Director

Forecast to breakeven in 2026

New minor risk - Financial position

Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi

Iovance Biotherapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Iovance Biotherapeutics, Inc., Annual General Meeting, Jun 11, 2024

Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results

Iovance Biotherapeutics, Inc. Agrees to A Proposed Settlement

Iovance Biotherapeutics: Initial Amtagvi Launch In Focus

Consensus revenue estimates increase by 11%

Iovance Biotherapeutics Announces Fda Has Lifted Clinical Hold on the Iov-Lun-202 Registrational Trial in Non-Small Cell Lung Cancer

New minor risk - Profitability

Iovance Biotherapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

New major risk - Share price stability

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million.

Price target increased by 19% to US$24.42

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million.

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million.

Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma

Consensus revenue estimates decrease by 25%

Iovance Biotherapeutics, Inc.’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma

New minor risk - Profitability

Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date

Iovance Biotherapeutics, Inc. Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer

Price target decreased by 8.7% to US$20.42

Consensus revenue estimates decrease by 71%

Iovance Biotherapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New major risk - Financial position

Independent Director recently bought US$27m worth of stock

Iovance Biotherapeutics, Inc. Announces U.S. Food and Drug Administration Updates

Price target decreased by 8.9% to US$22.36

Consensus revenue estimates decrease by 62%, EPS upgraded

New minor risk - Financial position

Iovance Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Shareholder dilution

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Price target increased by 13% to US$24.55

Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma

Consensus revenue estimates decrease by 21%, EPS upgraded

Iovance Biotherapeutics, Inc. Announces U.S. Food and Drug Administration Accepts the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

Consensus revenue estimates increase by 1,282%, EPS downgraded

Consensus revenue estimates decrease by 84%, EPS upgraded

Insufficient new directors

Consensus revenue estimates decrease by 15%, EPS upgraded

Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) entered into a definitive agreement to acquire Worldwide rights of Proleukin of Clinigen Limited fo

Interim CEO exercised options and sold US$234k worth of stock

Chief Medical Officer exercised options and sold US$67k worth of stock

Price target decreased to US$23.00

Independent Director recently bought US$62k worth of stock

Independent Director recently bought US$65m worth of stock

Price target decreased to US$23.77

Independent Director recently bought US$62k worth of stock

Iovance Biotherapeutics, Inc. Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma

Iovance Biotherapeutics, Inc. Announces Updated Clinical Data for Lifileucel in Advanced Melanoma At Society for Immunotherapy of Cancer (Sitc) Annual Meeting

Iovance Biotherapeutics, Inc. Announces Updated Clinical Data for Lifileucel in Advanced Melanoma At Society for Immunotherapy of Cancer (SITC) Annual Meeting

Iovance Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Iovance Biotherapeutics, Inc. Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte Therapy

Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates

Independent Director exercised options to buy US$440k worth of stock.

Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma

Iovance submits rolling license application to FDA for skin cancer treatment lifileucel

Calculating The Fair Value Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Price target decreased to US$25.17

Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss

Iovance: TIL Cell Therapy Set To Prove Itself

Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 1000 Dynamic Index

Iovance Biotherapeutics, Inc. Appoints Wendy L. Dixon to Board of Directors

Independent Director recently bought US$51k worth of stock